Biosimilars: Review of current applications, obstacles, and their future in medicine

World Journal of Clinical Cases
Flyn Kaida-YipDinesh Vyas

Abstract

Biosimilars are a growing drug class designed to be used interchangeably with biologics. Biologics are created in living cells and are typically large, complex proteins that may have a variety of uses. Within the field of gastroenterology alone, biologics are used to treat inflammatory bowel diseases, cancers, and endocrine disorders. While biologics have proven to be effective in treating or managing many diseases, patient access is often limited by high costs. The development of biosimilars is an attempt to reduce treatment costs. Biosimilars must be nearly identical to their reference biologics in terms of efficacy, side effect risk profile, and immunogenicity. Although the manufacturing process still involves production within living cells, biosimilars undergo fewer clinical trials than do their reference biologics. This ultimately reduces the cost of production and the cost of the biosimilar drug compared to its reference biologic. Currently, seven biosimilars have been approved by the United States Food and Drug Administration (FDA) for use in Crohn's disease, ulcerative colitis, and colorectal cancer. There are other biologics involved in treating gastroenterologic diseases for which there are no FDA approved biosimilars...Continue Reading

References

Sep 18, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H MellstedtH Ludwig
Jan 12, 2010·Nature Biotechnology·Huub Schellekens, Ellen Moors
Aug 2, 2012·Expert Opinion on Biological Therapy·Hans C EbbersHuub Schellekens
Jun 26, 2014·Expert Review of Clinical Immunology·Dae Hyun Yoo
Dec 23, 2014·MAbs·Dawn M EckerHoward L Levine
Jan 27, 2015·MAbs·Mark A SocinskiDolca Thomas
May 26, 2017·Journal of Pediatric Gastroenterology and Nutrition·Joanna Sieczkowska-GolubJaroslaw Kierkus
Oct 17, 2017·Rheumatology and Therapy·Mourad F Rezk, Burkhard Pieper

❮ Previous
Next ❯

Citations

Jan 4, 2020·Oncology Letters·Sofia KonstantinidouEleni Kokkotou
Dec 6, 2019·Expert Opinion on Biological Therapy·Yeong Wook SongJinseok Kim
Apr 1, 2020·Journal of Managed Care & Specialty Pharmacy·Shubha BhatFrancis A Farraye
Jun 8, 2021·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Aqsa SafdarMuhammad Zaman
Jul 15, 2021·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Simon W LamMandy Leonard
Jun 13, 2020·Bioconjugate Chemistry·Peter J ChoiJiney Jose

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.

Related Papers

Current Treatment Options in Gastroenterology
Frank I Scott, Gary R Lichtenstein
Expert Review of Clinical Pharmacology
Sean McConachiePramodini B Kale-Pradhan
Best Practice & Research. Clinical Gastroenterology
Akos IliasPeter L Lakatos
Minerva medica
Carla J GargalloFernando Gomollon
The American Journal of Managed Care
Valkal Bhatt
© 2022 Meta ULC. All rights reserved